Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations. (Q43611330)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Akito Hata

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Nobuyuki Katakami

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Hiroshige Yoshioka

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jumpei Takeshita

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kosuke Tanaka

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Shigeki Nanjo

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Reiko Kaji

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Yukihiro Imai

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kazuya Monden

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Takeshi Matsumoto

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kazuma Nagata

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kyoko Otsuka

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Ryo Tachikawa

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Keisuke Tomii

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Kei Kunimasa

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Masahiro Iwasaku

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Akihiro Nishiyama

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Tadashi Ishida

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Yoshihiro Nishimura

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

0 references

publication date

16 September 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

119

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

4325-4332

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28364

21 January 2018

Identifiers

10.1002/CNCR.28364

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24105277%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43611330&oldid=2101887331"